Statistics

Total Visits

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens44

Select a period of time:

Number of views in the range

Views
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens12

Views

Views
May 20250
June 20251
July 20256
August 20250
September 20251
October 20253
November 20251
Download CSV file
 untranslated
 untranslated

Top country views

Views
Brazil4
Mexico2
United States2
United Kingdom2
Colombia1
Tunisia1
 

Top cities views

Views
Anderson1
Bogotá1
Caruaru1
Curitiba1
Porto Alegre1
Puerto Vallarta1
Texcoco1
Tunis1
Wenceslau Guimarães1